Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

Every year, nearly 900,000 Americans are affected by venous thromboembolism (VTE), a condition in which blood clots form in ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

Elizabeth Simms was 27 and pregnant when she was struck with a life-threatening pulmonary embolism. Her fourth pregnancy had ...

Heparin entered clinical testing in the 1930s and, in combination with a vitamin K antagonist, was shown in the 1950s to be effective in the treatment of acute pulmonary embolism (MILESTONE 3).

The majority of fatal cases of pulmonary embolism in hospitalized patients occur in acutely ill, medically treated patients. Current guidelines, based on a large number of prospective, randomized, ...

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

The Johns Hopkins Armstrong Institute for Patient Safety and Quality leads national VTE prevention efforts through its Venous Thromboembolism (VTE) Collaborative, which aims to advance evidence-based ...

About the National Blood Clot Alliance: The National Blood Clot Alliance is the nation’s leading nonprofit voluntary health organization dedicated to advancing the prevention, early diagnosis, and ...

The first clinical practice guideline on acute pulmonary embolism (PE) from the American Heart Association and the American ...

Recent developments of interest in cardiovascular medicine ...